A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
Public ClinicalTrials.gov record NCT02553330. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.
Study identification
- NCT ID
- NCT02553330
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 90 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2015 (Actual)
- Primary completion
- Oct 3, 2017 (Actual)
- Completion
- Oct 3, 2017 (Actual)
- Last update posted
- Dec 16, 2020
2015 – 2017
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Hot Springs | Arkansas | — | — |
| Not listed | New Haven | Connecticut | — | — |
| Not listed | Trumbull | Connecticut | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Beverly | Massachusetts | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Clinton Township | Michigan | — | — |
| Not listed | Fort Gratiot | Michigan | — | — |
| Not listed | Fridley | Minnesota | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Katy | Texas | — | — |
| Not listed | Norfolk | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02553330, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2020 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02553330 live on ClinicalTrials.gov.